74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Anika Therapeutics Inc
Closed
SectorHealthcare
14.29 1.93
Overview
Share price change
24h
Min
12.89
Max
14.35
Income | 8.1M -22M |
|---|---|
Sales | -40M -1.3M |
EPS | -0.03 |
Profit margin | 1,694.961 |
Employees | 288 |
EBITDA | 52M 27M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +63.35% upside |
Next Earnings | 7 May 2025 |
|---|
Market Cap | -37M 199M |
|---|---|
Previous open | 12.36 |
Previous close | 14.29 |
Technical Score
By Trading Central
Confidence
Strong Bullish Evidence
Anika Therapeutics Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Anika Therapeutics Inc Forecast
Price Target
By TipRanks
63.35% upside
12 Months Forecast
Average 23 USD 63.35%
High 28 USD
Low 20 USD
Based on 3 Wall Street analysts offering 12 month price targets forAnika Therapeutics Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Anika Therapeutics Inc
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief. The company's joint preservation and restoration product family comprises and orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and Hyalomatrix used for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.
